glp-1 and rheumatoid arthritis Medications Arthritis: What the 2025 Research Actually Shows glp1 #rheumatology #arthritis #translationalresearch #clinicalresearch
Description
doi: 10.2337/db12-1116 58 KleinertMSachsSHabeggerKMHofmannSMMullerTD
Obesity Nearly all respondents cover GLP-1s for type 2 diabetes (T2D), versus only 39% who provide coverage for obesity
It will also be important to establish whether lower doses continue to protect against weight regain, and which patients benefit most from switching to oral therapies
During a two-year follow-up, 5,037 patients taking a GLP-1 developed diabetic retinopathy, compared with 4,938 who were not a 7% increased risk
doi: Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M
I.JavaidS.HameedA.et al (2024)
